BRAF and carcinoma: This leads us to hypothesize that applying a dual inhibition, or even a triple inhibition, for Akt and/or ERK and Hsp90 simultaneously, may prove to be effective to sensitize carcinomas possessing BRAF mutations to Hsp90 inhibitors.